IceCure has improved upon the technology and developed a system optimized for breast fibroadenoma. My patients have been very happy with the short, painless procedure, and the ability to return to normal activity immediately.” Andrew Kenler, MD, FACS. There are no events at the moment.
Show more
See More
1 day ago . IceCure Medical Ltd (ICCM) shares closed 0.9% lower than its previous 52 week low, giving the company a market cap of $237M. The stock is currently up 7350.0% year-to …
See More
IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation cryoablation technology that destroys tumors by freezing without the need for surgery, today ...
Show more
See More
* IceCure medical ltd - expects nmpa to complete its evaluation of amendment by end of 2022 * IceCure medical ltd- if amendment is approved, co expects to launch its commercial sales program for ...
Show more
See More
IceCure Medical Ltd. is a commercial stage medical device company, which engages in the research and development, design, manufacture, and marketing of cryoablation systems and technologies based ...
Show more
See More
About IceCure Medical. Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally-invasive technology is ...
Show more
See More
1 hour ago . IceCure submitted an amendment to the registration certificate granted for the IceSense3 System by China's NMPA, which will allow IceCure to sell its IceSense3 and Cryoprobes for commercial ...
Show more
See More
IceCure Medical’s ProSense machine, which uses liquid nitrogen to freeze tumors. (Courtesy) The Ice3 trial so far has focused on early stages of malignant tumors in low-risk candidates.
Show more
See More
Founded in 2006, Israel-based IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) develops and markets an advanced liquid-nitrogen-based …
Show more
See More
Stock analysis for IceCure Medical Ltd (ICCM:Tel Aviv) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
Show more
See More
IceCure Medical develops and markets minimally invasive cryoablation therapies for women's health and the general oncology market. The company's proprietary IceSense3 and ProSense systems provide minimally invasive, in-office definitive treatment for symptomatic tumors in various organs. The procedure is done under ultrasound or CT imaging to ...
Show more
See More
IceCure was co-founded by cryogenics expert Dr. Alex Levin and businessman Didier Toubia in 2006 as part of the Naiot Venture Accelerator in Yokneam, an incubator for IT and life science startups. IceSense is based on a technology Levin patented in 2002.
Show more
See More
IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer.
Show more
See More
IceCure Medical Ltd. is a commercial stage medical device company, which engages in the research and development, design, manufacture, and marketing of cryoablation systems and technologies based ...
Show more
See More
IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today ...
See More
IceCure is further pursuing FDA-specific approval for breast cancer with its ongoing ICE3 clinical trial, the largest controlled multilocation clinical trial in the U.S. for liquid nitrogen-based ...
Show more
See More
IceCure Medical. 1,389 likes · 46 talking about this · 14 were here. IceCure develops minimally-invasive solutions that use freezing to destroy tumors safely, quickly, and painlessly, without the...
Show more
See More
Overview IceCure develops minimally invasive products for the treatment of breast tumors and other internal diseased tissue. IceCure Medical Limited was founded in 2006.
Show more
See More
For example, IceCure is using forward looking statement in this press release when it discusses the development of distribution networks for its …
Show more
See More
IceCure is setting new standards in minimally-invasive tumor therapy for women’s health and interventional oncology. IceCure Medical is an Israeli medical device company founded in 2006 to advance treatment of cancerous tumors.
Ronen has over 15 years of experience as CFO in public and privately held companies in the medical device and communication infrastructure industries, including C. Mer Telecom Division and Insuline Medical.
IceCure’s next generation cryoablation technology, the ProSense™ system, enables rapid minimally-invasive, safe, and effective treatment of breast lesions in-office or ambulatory hospital settings.